PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Life-extending Drugs Drive Revenues in the U.S. Multiple Myeloma Market - Novel agents combined with established therapies are improving survival rates among myeloma patients, therefore allowing patients to live over five years with less cumbersome side effects
New Life-extending Drugs Drive Revenues in the U.S. Multiple Myeloma Market

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/04/16 - Novel agents combined with established therapies are improving survival rates among myeloma patients, therefore allowing patients to live over five years with less cumbersome side effects.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Particularly at the forefront of modern day multiple myeloma therapy are Thalomid, Revlimid, and Velcade—all fostering an unprecedented growth in the U.S. multiple myeloma market by generating millions in revenues. Thus, other early-stage development drugs hoping to emulate the success of the recent launches are likely to require partnerships to complete their development cycle.

New analysis from Frost & Sullivan (pharmaceutical.frost.com), U.S. Multiple Myeloma Market, reveals that revenues in this market totaled $930 million in 2006, and estimates this to reach $3.23 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Multiple Myeloma Market, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

“The introduction of Thalomid, Velcade and most recently Revlimid are producing record survival rates for patients with multiple myeloma, creating hope the disease will one day be chronically treated,” notes Frost & Sullivan Industry Analyst Jason McKinnie. “Additionally, these drugs are generating millions in revenues, helping the market grow at double-digit rates that attract new companies and continued research.”

Companies with products in the market and in development are hoping that new agents in combination with older agents will eventually lead to the treatment of myeloma as a chronic disease, or potentially extend survival by ten years or more. While this goal cannot be achieved in the immediate future, the increased response rates garnered by new agents have the potential to prevent the disease from progressing rapidly or too severely. Using combination therapy, longer progression-free survival will translate into increased revenues for not just a few companies, but a wide range of them.

Other the other hand, the lack of business development remains a major challenge confronting participants in the U.S. multiple myeloma market. There is a growing need to attract big pharmaceutical and biotechnology companies to help facilitate development in a disease that is growing more complex to treat.

“Treatment for multiple myeloma is becoming multifaceted with the recent entrance of new drugs, says McKinnie. “As a result, clinical trials are likely to increase in complexity, thereby creating additional costs. Given this, business development is of tremendous assistance to smaller companies in speeding up clinical trials and testing.”

While there are numerous drugs in the pipeline being developed by mostly smaller companies, the complexity of clinical trials could require small companies to obtain additional resources to continue development. Hence, smaller companies should analyze their needs and seek out mid-sized or larger companies for partnership in order to ensure enough resources for continued development. Well-designed preclinical tests, as well as significant responses in phase I trials, are likely to help attract larger pharmaceuticals and biotechnology companies.

U.S. Multiple Myeloma Market is part of the Pharmaceutical Subscription, which also includes research services in the following markets: U.S. colorectal cancer market– patient outlook, U.S. opioid and non-opiod pain management pharmaceuticals market, U.S. pulmonary arterial hypertension markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Life-extending Drugs Drive Revenues in the U.S. Multiple Myeloma Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)